ZYUS Life Sciences Corporation
ZLSCF
$0.5323
$0.133833.58%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.19% | -11.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.19% | -11.78% | |||
| Cost of Revenue | -1.86% | -95.88% | |||
| Gross Profit | 19.38% | 105.08% | |||
| SG&A Expenses | 19.27% | 15.76% | |||
| Depreciation & Amortization | 1.03% | -14.53% | |||
| Other Operating Expenses | -53.13% | -31.76% | |||
| Total Operating Expenses | 19.39% | -21.61% | |||
| Operating Income | -19.73% | 21.90% | |||
| Income Before Tax | -15.91% | 83.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.91% | 82.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.91% | 82.24% | |||
| EBIT | -19.73% | 21.90% | |||
| EBITDA | -24.46% | 32.41% | |||
| EPS Basic | -14.02% | 82.23% | |||
| Normalized Basic EPS | -13.79% | 19.16% | |||
| EPS Diluted | -16.98% | 82.24% | |||
| Normalized Diluted EPS | -13.79% | 19.16% | |||
| Average Basic Shares Outstanding | 1.69% | -0.02% | |||
| Average Diluted Shares Outstanding | 1.69% | -0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||